Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.56 |
| ▸ | NOS2 | P35228 | 8/20 | 0.56 |
| ▸ | NOS3 | P29474 | 6/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662318 | 1.00 | NOS1 (0.56) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL23682855 | 1.00 | NOS1 (0.56) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL23682813 | 0.94 | GSR (0.53) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL23815592 | 0.94 | GSR (0.53) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL304049 | 0.88 | SLC1A3 (0.46) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL304048 | 0.88 | SLC1A3 (0.46) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL13233386 | 0.84 | GSR (0.47) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL15710769 | 0.81 | SIGMAR1 (0.42) | MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL1851220 | 0.81 | NOS2 (0.53) | NOS1NOS2NOS3GSRDDAH1 | |
| SCHEMBL24642458 | 0.81 | GSR (0.52) | NOS1NOS2NOS3GSRDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20150079179-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120244192-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC. | 2012-09-27 | — | — | US | disclosed |
| EP-2424556-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | Jerini Ophthalmic Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110003756-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010126833-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-7727960-B2 | C5a receptor antagonists | JERINI AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20080161232-A1 | C5a is a cleavage product of the complement cascade, the CS convertase; antiinflammatory agents; autoimmune diseases; cyclic peptide compounds | JERINI AG (DE) | 2008-07-03 | — | — | US | disclosed |
| CN-101119724-A | Substituted pyrazoles as modulators of chemokine receptors | MERCK & CO INC (US) | 2008-02-06 | — | — | CN | disclosed |
| CN-101107264-A | C5a receptor antagonists | JERINI AG (DE) | 2008-01-16 | — | — | CN | disclosed |
| US-20060183883-A1 | C5a Receptor antagonists | JERINI AG (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183883-A1 | C5a Receptor antagonists | C5AR1, C3AR1, C5AR2 | NOS1 610/4885NOS2 811/4885NOS3 369/4885 |
| US-20110003756-A1 | C5a Receptor Antagonists | C5AR1, C3AR1, C5AR2 | NOS1 608/4885NOS2 718/4885NOS3 362/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | NOS1 4365/4885NOS2 4269/4885NOS3 4446/4885 |
| US-20080161232-A1 | C5a is a cleavage product of the complement cascade, the CS convertase; antiinflammatory agents; autoimmune diseases; cyclic peptide compounds | C3AR1, C5, C5AR1 | NOS1 621/4885NOS2 1018/4885NOS3 231/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | NOS1 4697/4885NOS2 4780/4885NOS3 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.